Hexadecylphosphocholine inhibits invasion of mouse T-cell lymphoma cells in two different invasion assays

Anticancer Research

Volumn 18, Issue 2 A, 1998, Pages 995-998

  Schaider, Helmut ^a   Seidl, Hannes ^a   Berger, Martin R ^b   Hofmann Wellenhof, Rainer ^a   Tritthart, Helmut A ^a   Smolle, Josef ^a  

^a UNIVERSITY OF GRAZ   (Austria)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Collagen type I gel; Devitalized dermis; Hexadecylphosphocholine (HePC); Invasion assay in vitro

Indexed keywords

ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; COLLAGEN TYPE 1; MILTEFOSINE; PHOSPHOLIPID;

ANIMAL CELL; ARTICLE; CANCER INVASION; CELL MIGRATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; IMAGE ANALYSIS; MICROSCOPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T CELL LYMPHOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; COLLAGEN; LYMPHOMA, T-CELL; MICE; NEOPLASM INVASIVENESS; PHOSPHORYLCHOLINE; TUMOR CELLS, CULTURED;

EID: 0031840918     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Berdel WE: Membrane-interactive lipids as experimental anticancer drugs. Br J Cancer 64: 208-11, 1991.
2. Fleer EAM: Biochemistry and possible clinical applications of etherlipids, especially of hexdecylphosphocholine (HePC). Dtsch Zschr Onkol 24: 10-7, 1992.
3. Sobottka SB, Berger MR, Eibl H: Structure-activity relationships of 4 anti-cancer alkylphosphocholine derivatives in vitro and in vivo. Int J Cancer 55:418-25, 1993.
4. Berger MR, Schmahl D: Protection by the alkyllysophospholipid, 1-octadecyl-2- methoxy-rac-glycero-3-phosphocholine, but not by the retinoid etretinate against leukemia development in DMBA-treated Long-Evans rats. Cancer Lett 30: 73-78, 1986.
5. Zeisig R, Arndt D, Brachwitz H: Etherlipid-Synthese und tumortherapeutische Verwendbarkeit. Pharmazie 45: 809-18, 1990.
6. Unger C: Alkylphosphocholine und Analoga-Entwicklung einer neuen Substanzgruppe mit antineoplastischer Wirkung. Stuttgart, Thieme, 1989.
7. Eibl H, Unger C: Hexadecylphosphocholine: a new and selective antitumor drug. Cancer Treat Rev 17: 233-42, 1990.
8. Unger C, Daamenz W, Fleer EAM, et al: Hexadecylphosphochline, a new etherlipid analogue: studies on the antineoplastic activity in vitro and in vivo. Acta Oncol 28: 213-27, 1989.
9. Unger C, Fleer E, Damenz H, Hilgard P, Nagel G, Eibl H: Hexadecylphosphocholine: Determination of serum concentrations in rats. J Lipid Mediat 5: 71-8, 1991.
10. Muschiol C, Berger MR, Schuler B, et al: Alkylphosphocholines: Toxicity and anticancer properties. Lipids 22: 930-4, 1987.
11. Vehmeyer K, Eibl H, Unger C: Hexadecylphosphocholine stimulates the colony- stimulating-factor dependent growth of hematopoietic cells. Exp Hematol 20: 1-5, 1992.
12. Kuhlencord A, Maniera T, Eibl H, Unger C: Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrob Agents Chemother 36: 1630-4, 1992.
13. Geilen CC, Wieder T, Reutter W: Hexadecylphosphocholine inhibits translocation of CTP:phosphocholine cytidylyltransferase in Madin-Darby canine kidney cells. J Biol Chem 267: 6719-24, 1992.
14. Uberall F, Oberhuber H, Maly K, Zaknun J, Demuth L, Grunicke HH: Hexadecylphosphocholine inhibits inositol phosphat formation and protein kinase C activity. Cancer Res 51: 807-12, 1991.
15. Zheng B, Oishi K, Shoji M et al: Inhibition of protein kinase C (sodium plus potassium)-activated adenosine triphosphatase, and sodium pump by synthetic phospholipid analogues. Cancer Res 50: 3025-31, 1990.
16. Berger MR, Reich S: The bone-marrow stimulatory activity of the antineoplastic agent hexadecylphosphocholine is abrogated by acetylcholine receptor blockade. Proc Annu Meet Am Assoc Cancer Res 34:A1997, 1993.
17. Burk K, David M, Junge K, Sindermann H: Overview on the clinical development of miltefosine solution (Miltex®) for the treatment of cutaneous breast cancer. Drugs of Today 30 (Suppl. B): 59-72, 1994.
18. Khayat D, Bonerandi JJ, Delaunay MM et al: Phase II study of 6% miltefosine solution (MIL) as a local treatment in cutaneous metastatic melanoma: preliminary results. International Congress on Anticancer Treatment, Feb 6th-9th, 259, 1996.
19. Schaider H, Tatzl R, Wilfert H, Wolf P, Kerl H, Metz J: Effizienz von Miltefosin® in der Behandlung von soliden Basaliomen. Hautarzt 105 (Suppl. 1): 100, 1997.
20. Dummer R, Krasovec M, Roger J, Sindermann H, Burg G: Topical administration of hexadecylphosphocholine in patients with cutaneous lymphomas: results of a phase I/II study. J Am Acad Dermatol 29: 963-70, 1993.
21. Vakaet L, Vleminckx K, van Roy F, Mareel M: Numerical evaluation of the invasion of closely related cell lines into collagen type I gels. Invasion Metastasis 11: 249-60, 1991.
22. Schor SL: Cell proliferation and migration on collagen substrata in vitro. J Cell Sci 41: 159-75, 1980.
23. Regnier M, Asselineau D, Lenoir MC: Human epidermis reconstructed on dermal substrates in vitro: an alternative to animals in skin pharmacology. Skin Pharmacol 3: 70-85, 1990.
24. Seidl H, Hofmann-Wellenhof R, Smolle J, Kerl H: A new method for quantification of tumor cell invasiveness and motility in vitro. Clin Exp Metastasis 12(5): 55, 1994.
25. Smolle J, Helige C, Tritthart HA: An image analysis and statistical evaluation program for the assessment of tumor cell invasion in vitro. Anal Cell Pathol 4: 49-57, 1992.
26. Smolle J, Grimmstad IA: Tumor cell motility within tumors determined by applying computer simulation to histologic patterns. Int J Cancer 50: 331-5, 1992.
27. Detmar M, Geilen CC, Wieder T, Orfanos CE, Reutter W: Phospholipid analogue Hexadecylphophocholine inhibits proliferation and phosphatidylcholine biosynthesis of human epidermal keratinocytes in vitro. J Invest Dermatol 102: 490-4, 1994.
28. Schallier DCC, Bruyneel EA, Storme GA, Hilgard P, Mareel MM: Antiinvasive activity of hexadecylphosophocholine in vitro. Anticancer Res 11: 1285-92, 1991.